1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from the PETAL consortium
    Journal Article

    Han, J. X.; Koh, M. J.; Boussi, L.; Sorial, M.; McCabe, S. M.; Peng, L.; Singh, S.; Eche-Ugwu, I. J.; Gabler, J.; Fernandez Turizo, M. J.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Shift from widespread to tailored antifungal prophylaxis in lymphoma patients treated with CD19 CAR T cell therapy: Results from a large retrospective cohort
    Journal Article

    Melica, G.; Luna de Abia, A.; Shah, G. L.; Devlin, S.; Corona, M.; Fein, J.; Dahi, P. B.; Giralt, S. A.; Lin, R. J.; Palomba, M. L.; more...
    Transplantation and Cellular Therapy (2025)

    Fulltext@MSK | Save
  • Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): A single-arm, open-label, phase 1, dose-escalation study
    Journal Article

    Iyer, S. P.; Sica, R. A.; Ho, P. J.; Prica, A.; Zain, J.; Foss, F. M.; Hu, B.; Beitinjaneh, A.; Weng, W. K.; Kim, Y. H.; more...
    Lancet Oncology (2025)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
    Journal Article

    Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chhabra, S.; Chabowska, M.; Dogan, A.; Falchi, L.; Grieve, C.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • New treatments for adult T-cell leukemia/lymphoma
    Review

    Epstein-Peterson, Z. D.; Gurumurthi, A.; Horwitz, S. M.
    Leukemia Research (2025)

    Fulltext@MSK | Save
  • Help or hindrance? Rituximab maintenance and COVID
    Editorial

    Noy, A.
    Haematologica (2025)

    Fulltext@MSK | Save
  • A phase II study of acimtamig (AFM13) in patients with CD30-positive, relapsed, or refractory peripheral T-cell lymphomas
    Journal Article

    Kim, W. S.; Shortt, J.; Zinzani, P. L.; Mikhailova, N.; Radeski, D.; Ribrag, V.; Domenech, E. D.; Sawas, A.; Alexis, K.; Emig, M.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes
    Journal Article

    Valtis, Y. K.; Devlin, S.; Shouval, R.; Rejeski, K.; Corona, M.; De Abia, A. L.; Rivas-Delgado, A.; Luttwak, E.; Cassanello, G.; Landego, I.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed and/or refractory follicular lymphoma after ≥ 2 prior therapies including those with a history of POD24: 4-year follow-up of a pivotal phase II study
    Meeting Abstract

    Shadman, M.; Bartlett, N. L.; Matasar, M.; Schuster, S. J.; Assouline, S. E.; Sehn, L. H.; Kuruvilla, J.; Giri, P.; Cheah, C. Y.; Dietrich, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Tumor determinants of response to CAR-T therapy in relapsed or refractory mantle cell lymphoma
    Meeting Abstract

    Epstein-Peterson, Z. D.; Ryan, C. E.; Devlin, S. M.; Accav, N. G.; Avigdor, A.; Corona, M.; Danylesko, I.; Dela Cruz, J.; Goy, A.; Jacobson, C. A.; more...
    Blood (2024)

    Fulltext@MSK | Save